4.8 Article

JNK-mediated disruption of bile acid homeostasis promotes intrahepatic cholangiocarcinoma

Publisher

NATL ACAD SCIENCES
DOI: 10.1073/pnas.2002672117

Keywords

JNK; PPARa; bile acid; cholangiocarcinoma

Funding

  1. La Caixa fellowship [RYC-2009-04972, RYC-2014-15242]
  2. European Regional Development Fund [CD19/00078]
  3. EU [260464]
  4. EFSD/Lilly European Diabetes Research Programme Dr. Sabio
  5. Leonardo Grant for Researchers and Cultural Creators, BBVA Foundation
  6. MINECO-FEDER [SAF2016-79126-R]
  7. Comunidad de Madrid
  8. La Asociacion Espanola contra el Cancer [IMMUNOTHERCAN-CM S2010/BMD-2326, B2017/BMD-3733]
  9. European Cooperation in Science & Technology (COST) Action [CA17112]
  10. MINECO Retos
  11. AMMF Cholangiocarcinoma Charity [SAF2016-78711]
  12. NIH [2018/117, NanoLiver-CM Y2018/NMT-4949, UCM-25-2019, DK R01 DK107220]
  13. Carlos III Institute of Health, Spain [PI16/00598]
  14. Ministerio de Ciencia, Innovacion y Universidades
  15. Pro-CNIC Foundation
  16. [SEV-2015-0505]

Ask authors/readers for more resources

Metabolic stress causes activation of the cJun NH2-terminal kinase (JNK) signal transduction pathway. It is established that one con-sequence of JNK activation is the development of insulin resistance and hepatic steatosis through inhibition of the transcription factor PPAR alpha. Indeed, JNK1/2 deficiency in hepatocytes protects against the development of steatosis, suggesting that JNK inhibition repre-sents a possible treatment for this disease. However, the long-term consequences of JNK inhibition have not been evaluated. Here we demonstrate that hepatic JNK controls bile acid production. We found that hepatic JNK deficiency alters cholesterol metabolism and bile acid synthesis, conjugation, and transport, resulting in cholestasis, increased cholangiocyte proliferation, and intrahepatic cholangiocarcinoma. Gene ablation studies confirmed that PPAR alpha mediated these effects of JNK in hepatocytes. This analysis highlights potential consequences of long-term use of JNK inhibitors for the treatment of metabolic syndrome.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available